Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ: ZURA )

1.415 -0.025 (-1.74%)
Streaming Delayed Price Updated: 3:14 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129,651
Open 1.440
Bid (Size) 1.410 (12)
Ask (Size) 1.420 (4)
Prev. Close 1.440
Today's Range 1.380 - 1.480
52wk Range 0.9700 - 6.350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
From Zura Bio Limited
Via Business Wire

Performance

YTD
-39.79%
-39.79%
1 Month
+4.81%
+4.81%
3 Month
-20.95%
-20.95%
6 Month
-69.50%
-69.50%
1 Year
-59.34%
-59.34%

More News

Read More
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024
Via InvestorPlace
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
Zura Bio to Participate in Two Upcoming Investor Conferences in November
From Zura Bio
Via Business Wire
Zura Bio to Present at Three Upcoming Investor Conferences in September
From Zura Bio Limited
Via Business Wire
ZURA Stock Earnings: Zura Bio Misses EPS for Q2 2024
Via InvestorPlace
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
From Zura Bio Limited
Via Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
3 Undervalued Biotech Stocks With Breakout Potential
Via InvestorPlace
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
From Zura Bio Limited
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
From Zura Bio Limited
Via Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation in June Investor Conferences
From Zura Bio Limited
Via Business Wire
3 Penny Stocks to Buy Now: May 2024
Via InvestorPlace
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
From Zura Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.